With Nippon India, Morgan Stanley, and Motilal Oswal backing block deals, HCG strengthens its oncology leadership—supported by rising cancer prevalence, expanding centers, and bullish technical and financial momentum.
By S JHA
MUMBAI, September 13, 2025 — Healthcare Global Enterprises (HCG), India’s leading oncology care network, attracted strong institutional interest this week, with major block deals suggesting renewed investor confidence. Shares of Healthcare Global Enterprises closed at ₹678, with minor cuts on Friday.
“Nippon India Mutual Fund led the buying spree, acquiring 44 lakh shares at ₹695 apiece, joined by Morgan Stanley Asia Singapore (8.8 lakh shares), Plutus Wealth (7.2 lakh shares), and Motilal Oswal MF (3 lakh shares),” said StockEdge in a note shared on its Telegram channel.
The surge in institutional demand comes at a critical moment. India faces a mounting cancer challenge: 1 in 9 Indians may develop cancer by 2025, with early detection still abysmally low in breast, head-and-neck, and lung cancers. Against this backdrop, HCG has expanded to 25 centers across 19 cities, with 400+ oncologists, advanced LINAC radiotherapy platforms, robotic surgical systems, and genomics-driven diagnostics.
Financial Performance Snapshot (FY25):
- Revenue: ₹2,223 crore
- EBITDA Margin: 17.4%
- PAT Margin: 2.0%
- OPD footfall: 4.35 lakh
- Robotic surgeries: 1,077
- CAPEX: ₹206 crore
While profitability remains thin, HCG’s asset-light model (leasing, pay-per-use, hub-and-spoke) has enabled rapid scaling with lower capital intensity. Its revenue mix of 52% metros and 48% non-metros positions it well for India’s rising Tier-2/Tier-3 healthcare demand.
Technical Analysis: HCG stock has broken out from a consolidation zone on the daily charts, forming a bullish flag pattern—typically a continuation signal. The strong delivery volumes accompanying the breakout validate institutional accumulation.
- Key support: ₹660–670 (recent breakout zone)
- Immediate resistance: ₹730–740
- Momentum indicators (RSI, MACD): bullish crossover, suggesting upside momentum.
- Medium-term trend: Strong, with potential to retest ₹800+ if broader market sentiment holds.
Outlook: HCG’s dual strategy—expanding cancer care access beyond metros while integrating advanced diagnostics and robotics—aligns with India’s projected 13–14% oncology market CAGR. Backed by institutional inflows and improving operating efficiency, the stock is well-positioned for re-rating, though thin net margins remain a risk.
Shares of Healthcare Global Enterprises have risen by 36% in the last six months. The stock is in a consolidation phase for over a month now.
(Disclaimer: This article makes no recommendation for buy or sell of shares of any company)
Follow The Raisina Hills on WhatsApp, Instagram, YouTube, Facebook, and LinkedIn
